In short
Pfizer Inc (PFE) has revenue down 1.6% to $62.6B and net income down 3.2% to $7.8B year on year. Its net margin is 12.4%, and it trades at 44.7× trailing earnings. Fisclear flags 1 medium-severity risk and no high-severity ones. How we calculate this
Compare: JNJ vs PFE · ABBV vs PFE · MRK vs PFE · LLY vs PFE
Valuation
HealthcareLive · Yahoo FinancePrice
$27.40
$156.2B
8.2x
6.28%
52-Week Range
Decision Context
Market appears to be pricing in less growth than this company's historical average, suggesting potential upside if the trajectory continues. Quality and efficiency scores support the business case.
Based on filing period ending Sept 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
Fed Funds Rate
3.88%
Accommodative
10-Year Treasury
5.13%
2026-10-01
Unemployment
4.2%
Near full employment
CPI Index
336.3
2026-09-01
M2 Money Supply
$23.4T
2026-09-01
The Federal Funds rate stands at 3.88% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 5.13%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.2%; Industrial production index is at 104.0; M2 money supply is $23.4T; CPI index stands at 336.3.
SWOT Analysis — PFE
Inflationary BoomStrengths
No standout strengths identified from the filing.
Weaknesses
Operating Cash Flow: $11.7B (-8.2% YoY) — Operating cash flow fell 8% but remained positive.
EPS (Diluted): $1.36 (-3.5% YoY) — Earnings per share fell 4%.
Net Income: $7.8B (-3.2% YoY) — Profit fell 3% but remained positive.
Total Assets: $208.2B (-2.5% YoY) — Total assets shrank 2% — the balance sheet contracted.
Revenue: $62.6B (-1.6% YoY) — Revenue fell 2% — the company generated less from its core operations.
Stock is near its 52-week high (31.33) — the price reflects strong recent momentum, but entry risk is elevated at these levels.
Opportunities
No clear opportunities identified at this time.
Threats
Current ratio of 1.16x — thin liquidity buffer against short-term obligations.
Year-over-Year Changes
Operating Cash Flow
$11.7B
was $12.7B
Operating cash flow fell 8% but remained positive.
EPS (Diluted)
$1.36
was $1.41
Earnings per share fell 4%.
Net Income
$7.8B
was $8.0B
Profit fell 3% but remained positive.
Total Assets
$208.2B
was $213.4B
Total assets shrank 2% — the balance sheet contracted.
Revenue
$62.6B
was $63.6B
Revenue fell 2% — the company generated less from its core operations.
Risk Flags
0 high · 1 medium · 1 low- ◈ Medium
Current ratio of 1.16x — thin liquidity buffer against short-term obligations.
- ○ Low
Stock is near its 52-week high (31.33) — the price reflects strong recent momentum, but entry risk is elevated at these levels.
Technical Signals
Daily closes · 1-year dataPfizer Inc: common questions
Is Pfizer Inc profitable?
Yes. Pfizer Inc made a net profit of $7.8B in its latest fiscal year (fiscal 2025), a net margin of 12.4%.
Is Pfizer Inc's revenue growing?
No. Revenue fell 1.6% year on year, to $62.6B.
What is Pfizer Inc's P/E ratio?
Pfizer Inc trades at 39.1× its trailing twelve-month earnings. In other words, the share price is about 39 times the profit per share the company earned over the past year.
Does Pfizer Inc pay a dividend?
Yes. Pfizer Inc's forward dividend yield is 6.28%, the expected annual dividend as a share of the current share price.
What are the main risks for Pfizer Inc?
Fisclear's checks flag 1 medium- or high-severity risk. The most serious: Current ratio of 1.16x — thin liquidity buffer against short-term obligations.
Answers are generated from the figures in this report (updated 5 Nov 2026). Information, not investment advice.
Latest News
via FinnhubFiling History — PFE
Get the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade PFE
Links open broker research pages. Not an endorsement or recommendation.
Research Pfizer Inc
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.